Clinical Trial Update: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) [Phase 2]

View source ↗

Summary

Pembrolizumab is being studied in a Phase 2 trial (MK-3475-158/KEYNOTE-158) for advanced solid tumors; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anal Cancer
• Cervical Cancer
• Cholangiocarcinoma
• Colorectal Cancer
• Endometrial Cancer
• Mesothelioma
• Small Cell Lung Cancer
• Vulvar Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Advanced Cancer, Anal Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING